Inversago Pharma
@inversago
Inversago Pharma is a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, leading the way in peripheral CB1 blockade.
ID: 3254763264
http://inversago.com 24-06-2015 17:22:22
353 Tweet
196 Followers
214 Following
De nouvelles données sur le INV-202 d'Inversago Pharma ont été présentées ce matin à #ATS2023 par Carolyn R. Morris, Chercheuse facultaire, Larner College of Medicine, University of Vermont. Apprenez-en plus sur inversago.com/fr/nouvelles
New data about Inversago Pharma's INV-202 were presented this morning at #ATS2023 by Carolyn R. Morris, PhD, Faculty Scientist, University of Vermont. More details on inversago.com/en/news
As the Inversago Pharma team prepares for the #1000km cycling challenge of Grand Défi Pierre Lavoie, we thank all our sponsors for their pivotal support: @robiccanada, White & Case LLP, Osler, Hoskin & Harcourt LLP, #CorealisPharma, Domain Therapeutics, #GenvionCorp, @NuChemSciences, #RMMSattorneys. 🙏🚴♀️
À l'agenda : Inversago Pharma présentera des données cliniques de #Phase1b sur le INV-202 lors des 83es rencontres scientifiques de l'American Diabetes Association qui se tiendront à #SanDiego (CA). Communiqué complet sur inversago.com
Save the date: Inversago Pharma will present data on INV-202 #Phase1b at the 83rd Scientific Sessions of American Diabetes Association to be held in #SanDiego, CA. Full release on inversago.com
Inversago Pharma team takes part to the Grand Défi Pierre Lavoie to raise funds and awareness on rare diseases. Scan the QR code to learn more.
Inversago Pharma présente des données de l’étude de #Phase1b sur le INV-202 lors du 83e congrès de l’ADA. Présentation d’affiche lundi 26 juin à 11h30am HP. Observations disponibles dès maintenant sur inversago.com tinyurl.com/2p8rd4zy #CB1 #Pertedepoids
Inversago Pharma presents data from INV-202 #Phase1b at the 83rd ADA Scientific Sessions. Live poster presentation on Monday, June 26, 11:30am PT. Findings available now on inversago.com tinyurl.com/4btwn3db #CB1blockade #Weightloss
Inversago Pharma a débuté une #phase1 pour évaluer l’innocuité, la tolérance et les caractéristiques pharmacocinétiques du INV-347, un inhibiteur oral de petite taille du récepteur CB1. La société procède aussi à une 2e #phase2 sur le INV-202 chez des personnes atteintes d’obésité.
Inversago Pharma has initiated a #phase1 trial on INV-347, a next generation, oral small molecule CB1 blocker to investigate its safety, tolerability and pharmacokinetics. The company is also conducting a second #phase2 trial with INV-202 in people with obesity.
💻 Join us 3-28-24 for the adMare Industry Builder Series with @fravenellee! François will share the journey behind Inversago Pharma's $1+ billion acquisition by Novo Nordisk. Discover key decisions made & obstacles the team overcame along the way. ✍️ Register now!
Led by our VP and General Counsel Jean-Daniel Bélanger, Team Inversago Pharma gets ready for the 1000km Challenge, part of Le Grand Défi Pierre Lavoie. Learn more on inversago.com 🚴♀️🚴🚴♂️
Inversago Pharma is pleased to announce the appointment of two new vice-presidents to its leadership team: Geneviève Gaucher, VP Preclinical Development and Adriana DiMarco, VP CMC and Regulatory Affairs. More on their respective roles and backgrounds on inversago.com
Thank you François Ravenelle for your exceptional leadership of Inversago Pharma. Welcome, Micheline Beauvais, as you write an exciting new chapter with us as our new CEO. inversago.com
